Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro.

Rubin BK, Kater AP, Goldstein AL

Chest1 Nov 2006Cited by 24 (Europe PMC)

PMID17099021DOI10.1378/chest.130.5.1433PepBankPUB-17099021

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueEfficacy outcome
In cystic fibrosis sputum in vitro, Tbeta4 decreased sputum cohesivity with a dose-dependent threshold.
In plain wordsIn lab tests on cystic fibrosis sputum, thymosin beta4 made the sputum less sticky once the dose passed a threshold.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseSputum cohesivity with Tbeta4 by dose
Study
humann = 17
cystic fibrosis sputum
Outcome group
Respiratory function · Respiratory
Studied dose
0.3, 3, 30, and 150 microg/mLAs given in this study (human).
Source sentences
Summary
There was a dose-dependent threshold decrease in cohesivity with Tbeta4 and a time-dependent decrease in cohesivity over 60 min at 30 microg/mL.
1 context sentence(design, population, supporting numbers)
Summary · context
Sputum was collected during pulmonary function testing from 17 subjects during a cystic fibrosis (CF) center visit.
Report a problemFND-1709902101
02LabEx vivo tissueEfficacy outcome
In cystic fibrosis sputum in vitro, Tbeta4 at 30 microg/mL decreased sputum cohesivity in a time-dependent way over 60 min.
In plain wordsIn lab tests on cystic fibrosis sputum, thymosin beta4 made the sputum less sticky as time passed.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseSputum cohesivity with Tbeta4 over time
Study
humann = 17
cystic fibrosis sputum
Outcome group
Respiratory function · Respiratory
Studied dose
30 microg/mL · 0, 10, 20, or 60 minAs given in this study (human).
Source sentences
Summary
There was a dose-dependent threshold decrease in cohesivity with Tbeta4 and a time-dependent decrease in cohesivity over 60 min at 30 microg/mL.
1 context sentence(design, population, supporting numbers)
Summary · context
Sputum was collected during pulmonary function testing from 17 subjects during a cystic fibrosis (CF) center visit.
Report a problemFND-1709902102
03LabEx vivo tissueEfficacy outcome
In cystic fibrosis sputum in vitro, Tbeta4 alone at any concentration did not significantly change cough or mucociliary transportability.
In plain wordsIn lab tests on cystic fibrosis sputum, thymosin beta4 alone did not change how well sputum moved by cough or cilia.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeCough and mucociliary transportability with Tbeta4 alone
Study
humann = 17
cystic fibrosis sputum
Comparator
Control
Outcome group
Respiratory function · Respiratory
Studied dose
0.3, 3, 30, and 150 microg/mLAs given in this study (human).
Source sentences
Summary
There was a 44% increase in cough transportability of sputum in vitro (p = 0.037) and a 71% increase in mucociliary transportability of sputum in vitro (p = 0.013) relative to control with the combination of dornase alfa and Tbeta4, but no significant change with dornase alfa or Tbeta4 alone at any concentration.
1 context sentence(design, population, supporting numbers)
Summary · context
Sputum was collected during pulmonary function testing from 17 subjects during a cystic fibrosis (CF) center visit.
Report a problemFND-1709902103

Studies that did not test the peptide alone4

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

04LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueEfficacy outcome
In cystic fibrosis sputum in vitro, the combination of dornase alfa and Tbeta4 at 1.5 microg/mL each decreased G*s by 70%.
In plain wordsIn lab tests on cystic fibrosis sputum, thymosin beta4 combined with dornase alfa reduced a measure of sputum stiffness by 70%.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseSputum G*s with dornase alfa plus Tbeta4
Study
humann = 17
cystic fibrosis sputum
Outcome group
Respiratory function · Respiratory
Measurements
G*s decrease
70%
dornase alfa + Tbeta4 1.5 microg/mL each
Source sentences
Summary
there was a 70% decrease in G*s and a 65% decrease in G' at 1 rad/s (p = 0.013).
1 context sentence(design, population, supporting numbers)
Summary · context
Sputum was collected during pulmonary function testing from 17 subjects during a cystic fibrosis (CF) center visit.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-1709902104
05LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueEfficacy outcome
In cystic fibrosis sputum in vitro, the combination of dornase alfa and Tbeta4 at 1.5 microg/mL each decreased G' by 65% at 1 rad/s.
In plain wordsIn lab tests on cystic fibrosis sputum, thymosin beta4 combined with dornase alfa reduced sputum elasticity by 65%.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseSputum G' with dornase alfa plus Tbeta4
Study
humann = 17
cystic fibrosis sputum
Outcome group
Respiratory function · Respiratory
Measurements
G' decrease
65%
dornase alfa + Tbeta4 1.5 microg/mL each
Source sentences
Summary
With the combination of dornase alfa and Tbeta4 at 1.5 microg/mL each, there was a 70% decrease in G*s and a 65% decrease in G' at 1 rad/s (p = 0.013).
1 context sentence(design, population, supporting numbers)
Summary · context
Sputum was collected during pulmonary function testing from 17 subjects during a cystic fibrosis (CF) center visit.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-1709902105
06LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueEfficacy outcome
In cystic fibrosis sputum in vitro, the combination of dornase alfa and Tbeta4 increased cough transportability by 44% versus control.
In plain wordsIn lab tests on cystic fibrosis sputum, thymosin beta4 combined with dornase alfa improved cough transport by 44% compared with control.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseCough transportability with dornase alfa plus Tbeta4
Study
humann = 17
cystic fibrosis sputum
Comparator
Control
Outcome group
Respiratory function · Respiratory
Measurements
cough transportability increase
44%
dornase alfa + Tbeta4
Source sentences
Summary
There was a 44% increase in cough transportability of sputum in vitro (p = 0.037) and a 71% increase in mucociliary transportability of sputum in vitro (p = 0.013) relative to control with the combination of dornase alfa and Tbeta4,
1 context sentence(design, population, supporting numbers)
Summary · context
Sputum was collected during pulmonary function testing from 17 subjects during a cystic fibrosis (CF) center visit.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-1709902106
07LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueEfficacy outcome
In cystic fibrosis sputum in vitro, the combination of dornase alfa and Tbeta4 increased mucociliary transportability by 71% versus control.
In plain wordsIn lab tests on cystic fibrosis sputum, thymosin beta4 combined with dornase alfa improved cilia transport by 71% compared with control.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseMucociliary transportability with dornase alfa plus Tbeta4
Study
humann = 17
cystic fibrosis sputum
Comparator
Control
Outcome group
Respiratory function · Respiratory
Measurements
mucociliary transportability increase
71%
dornase alfa + Tbeta4
Source sentences
Summary
and a 71% increase in mucociliary transportability of sputum in vitro (p = 0.013) relative to control with the combination of dornase alfa and Tbeta4
1 context sentence(design, population, supporting numbers)
Summary · context
Sputum was collected during pulmonary function testing from 17 subjects during a cystic fibrosis (CF) center visit.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-1709902107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.